OBJECTIVE: To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity. METHODS: The paper reviews current and investigational antiobesity drugs. RESULTS: At present, there are only few drugs approved by the Food and Drug Administration (FDA) for the treatment of adult obesity. The most important ones are sibutramine and orlistat. The FDA in the USA approved the latter drug in 2003, and it has recently been approved by the European Union for the treatment of adolescents. There are several investigational antiobesity agents but only few new and promising substances like Rimonabant (a cannabinoid receptor antagonist) and axokine (ciliary neutrotrophic factor) are already at an advanced stage of development. CONCLUSION: In adults, it seems to be justified using drugs for long-term treatment of 'medically important' obesity. Strict guidelines concerning the treatment of obese adolescents with orlistat are needed. It is only hoped that double-blind placebocontrolled studies investigating the new and promising drugs will also include adolescents and provide sufficient scientific data to get them licensed for the treatment of obese adolescents.
Introduction
Historically, a fat child meant a healthy child, who was likely to survive undernourishment and infections. In the past few decades, however, excessive fatness has undoubtedly become the primary childhood health problem in developed nations and, to some degree, in other parts of the world. [1] [2] [3] [4] Successful methods to prevent paediatric overweight remain elusive and ineffective, long-term weight reduction programs are also not very effective. Although some data suggest that behavioural treatment of obesity may be more effective for children and adolescents than for adults, 5 even the best studies find long-term weight reductions maintained in only about half of children and adolescents treated with intensive behavioural modification. 5, 6 Successful behavioural programs are time and labour consuming and require intensive parental involvement, which, for many families, is simply not realistic. As a result, paediatricians tend to turn to and expect help from pharmacotherapy, especially in extreme obesity being resistant to conventional weightreducing programs. The present paper focuses on pharmacotherapy of obesity and agents under development. It is intended to update paediatricians in this rapidly progressing field and to give indications for eventual drug support in childhood obesity.
Current therapies
At present, there are few drugs approved by the Food and Drug Administration (FDA) ( Table 1) for the treatment of adult obesity and only two of these are widely used in clinical practice (sibutramine and orlistat). These latter drugs are discussed below.
Appetite suppressantFnoradrenergic/serotoninergic agent (sibutramine) This drug has been approved by FDA and registered in many countries. It is a serotonin and noradrenaline reuptake inhibitor. Devoid of antidepressant effect, it decreases food intake through its action on b 1 and 5-HT 2A/2C receptors, and is thought to enhance metabolic activity through the stimulation of peripheral b 3 receptors. 7, 8 The sibutramineassociated weight loss occurs within the first 6 months of treatment, and it may be maintained for at least 2 y. 9,10 It may have favourable effects on cardiovascular risk factors, as well as improving glucose control in patients with diabetes. 11, 12 However, because patients administered sibutramine may experience increases in blood pressure and heart rate, sibutramine is contraindicated in patients with uncontrolled hypertension, cardiac dysrhythmias, congestive heart failure, or stroke. 13 In a randomised double-blind placebo-controlled trial, 82 adolescents were treated with sibutramine in combination with behavioural therapy.
14 Sibutramine significantly increased weight loss during the 6 months treatment as compared to the placebo group. However, the medication was reduced in 23 or discontinued in 10 patients to manage hypertension or other symptoms. There were no differences between groups in changes in cholesterol, triglycerides, serum insulin, glucose or homeostasis model of insulin sensitivity. In a more recent study, 60 adolescents were investigated for 6 months in a randomised double-blind placebo controlled trial. 15 Sibutramine significantly improved weight loss and no adverse effects were observed. The results of the above studies are promising, but the duration of the studies was too short and the number of patients included was low. Therefore, larger and longer studies are needed to assess the benefits and hazards of sibutramine treatment in obese adolescents.
Digestive inhibitorFlipase inhibitor (orlistat)
Orlistat is a potent and irreversible inhibitor of gastric, and pancreatic carboxylester lipases, 16 thus decreasing the hydrolysis of the ingested triglycerides. It produces a dosedependent reduction in dietary fat absorption, which is nearly maximal at a dose of 120 mg thrice daily. According to the results of the European Multicenter Orlistat Study, 17 orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-y period. Orlistat has also been shown to reduce the percentage of subjects with impaired glucose tolerance who progress to develop overt diabetes mellitus, and it causes significant reductions in total and low-density lipoprotein cholesterol and in systolic and diastolic blood pressure. 18, 19 Adverse effects of orlistat are predominantly related to fat malabsorption (loose stools, faecal urgency, fat-soluble vitamin deficiency). Although absolute concentrations of vitamins D and E and b-carotene decreased during orlistat treatment, only few individuals needed supplementation in the European Multicenter Orlistat Study. 17 Two studies in extremely obese adolescents 20, 21 and one study in obese prepubertal children 22 demonstrated that orlistat significantly reduces body weight. Unfortunately, all these studies were short-term trials (3 months), and only few patients remained on orlistat treatment for 15 months. The number of patients investigated was low: twenty, 20 twenty two, 21 and eleven. 22 What is more disturbing is that none of these trials were randomised and placebo-controlled. The orlistat treatment had a side effect profile similar to that observed in adults, but its true benefit vs conventional therapy remained to be determined in placebo-controlled trials. The results of a randomised, 54-week double-blind, placebo-controlled study investigating the safety and efficacy of orlistat in obese adolescents were presented at the 13th European Congress on Obesity, Prague in 2004 23 and published recently in JAMA. 24 The study included 539 adolescents (357 on 120 mg orlistat, 182 on placebo), but only 349 completed (232 active, 117 placebo) the study. The results showed that adolescents treated with orlistat had a significantly greater reduction in body weight, BMI and in waist circumference. There were no differences between groups in changes in fasting cholesterol, triglyceride, fasting insulin and glucose levels. The drug was well tolerated. Since orlistat reduces the absorption of lipid soluble vitamins, multivitamin supplementation and monitoring of the serum concentration of lipid soluble vitamins, especially vitamin D levels, is necessary in children and adolescents on orlistat treatment. On the basis of the above study, the FDA approved the use of orlistat in obese adolescents at the end of 2003, and it has been recently (June 2005) approved for subjects from 12 y of age in Europe, too. One can certainly argue whether the data of one study treating 232 adolescent with orlistat for 54 weeks provide sufficient scientific basis for such a decision affecting large number of adolescents.
Investigational antiobesity agents
Great effort and huge amount of money have been and are devoted to the development of new antiobesity drugs. There are hundreds of molecules under investigation. Examples of these are listed in Table 2 . It is beyond the scope of the present paper to review all these promising antiobesity agents (for a review see Bays 25 ). Only those being in an advanced phase of development will be discussed.
Topiramate is a derivative of the naturally occurring sugar monosaccharide D-fructose and was originally developed as a diabetes treatment, but finally it was licensed as an antiseizure drug. Later topiramate has been shown to induce weight loss. According to the review of Astrup et al, 26 'the Rimonabant is an example of a cannabinoid (CB) receptor antagonist that blocks CB-1 receptor, which may be involved with appetite. It was developed through the observation that cannabis smokers may experience increased appetite. Rimonabant may increase satiety and cause weight reduction. It is currently under development as an antiobesity agent. In a recent randomised, 1-y double-blind, placebo-controlled study, rimonabant promoted significant decrease of body weight, waist circumference, and improvement in cardiovascular risk factors. 27 Comprehensive reviews 28, 29 discussing the possible role of leptin in the development and treatment of human obesity have been published. Leptin seemed to be an attractive candidate for the treatment of obesity as it is an endogenous protein, and beside other functions it regulates body fat stores. Unfortunately, most obese people have high leptin plasma levels, and there is only a small subset of patients with leptin deficiency, who certainly benefit from leptin administration. 30 According to the most recent update of the human obesity gene map, 173 human obesity cases due to single-gene mutations are known of which only six cases are due to leptin deficiency. 31 In a recent paper, Gibson et al 32 reported the effects of 4 y leptin therapy in a child with congenital leptin deficiency. At 4 y of therapy with subcutaneous injection of recombinant leptin provided further evidence for the beneficial effects of sustained leptin replacement on fat mass, hyperinsulinaemia, hyperlipidaemia and thyroid function. Although obese individuals have increased serum concentration of leptin and concomitant leptin resistance, therapeutic augmentation of the circulating leptin levels by peripheral administration of leptin seemed reasonable. Unfortunately, while some clinical trials have suggested modest benefit with peripheral leptin or leptin analogue administration, other studies have been disappointing. 33, 34 The results generally suggest that it may be more appropriate to use leptin as an agent to reduce regain of weight lost by other strategies. Nonetheless, leptin analogues or agonists are undergoing development that may prove to be more effective than native leptin. Leptin-like effects may also be increased through ciliary neutrotrophic factor (CNTF). CNTF was first evaluated for potential treatment of amyotropic lateral sclerosis, and was found by chance to result in weight loss. Axokine is a secondgeneration variant of CNTF that seems to activate leptin-like postreceptor mechanisms in leptin-resistant animals. Axokine has been shown to promote weight reduction in early clinical trials. 35 Axokine is currently evaluated in obese and type 2 diabetic patients in phase III clinical studies.
Conclusion
In adults, it seems to be justified using drugs for long-term treatment of 'medically important' obesity. The newest and most important development concerning drug therapy of obesity is that orlistat has been licensed for the treatment of adolescents in the USA and in the European Union. Until now there has been a consensus among paediatricians that drug treatment is not justified and not recommended in children and adolescents. Now, that orlistat is approved in the United States and in Europe for adolescents 12 y and above, we face the problem that the prescription of orlistat for the treatment of adolescent obesity might increase dramatically. In extremely obese adolescents with obesityrelated comorbidities being resistant to conventional weightreducing programs, and in patients with Prader-Willi syndrome, a rationale for pharmacological treatment could easily be established, but in the majority of cases the indication of drug therapy, the evaluation of benefit/risk ratio is much more difficult. It is an urgent task therefore to work out guidelines defining the following: (1) indications of treatment, (2) who should indicate and supervise the treatment (obesity expert It is only hoped that double-blind placebo-controlled studies investigating the efficacy and side effects of some new and promising drugs will also include adolescents and provide sufficient data to get them licensed for the treatment of this age group, too. The need for such studies is even more pressing in the case of drugs used for the treatment of obesity-associated diseases (metformin, statins, etc).
